Active ingredients: tenofovir disoproxil + emtricitabine + elvitegravir + cobicistat
What it is used for
STRIBILD is indicated as a single tablet regimen for the treatment of HIV infection in treatment-naïve adults. STRIBILD is also indicated in certain virologically suppressed (HIV1 RNA <50 copies/mL) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see Clinical Trials). Patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of STRIBILD (tenofovir DF, emtricitabine or elvitegravir). STRIBILD is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide HIV-1 reverse transcriptase inhibitors.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Film coated, green, capsule-shaped tablets, debossed with 'GSI' on one side and '1' in a square box on the other side.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient tenofovir disoproxil + emtricitabine + elvitegravir + cobicistat
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems